2019
SY6-1 Cancer immunotherapy; A paradigm shift in the first-line treatment of lung cancer
Herbst R. SY6-1 Cancer immunotherapy; A paradigm shift in the first-line treatment of lung cancer. Annals Of Oncology 2019, 30: vi32. DOI: 10.1093/annonc/mdz325.Peer-Reviewed Original ResearchLung cancerImmune checkpoint inhibitorsFirst-line treatmentMinority of patientsTumor mutational burdenPresence of tumorEfficient trial designMarker of resistanceCheckpoint inhibitorsTreatment of cancerCancer deathCancer immunotherapyPredictive markerSmoking ratesMutational burdenNew therapiesTrial designImmune systemCancerTherapyImmunotherapyChemotherapyPatientsTreatmentMarkers
2016
Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer
Morgensztern D, Herbst RS. Nivolumab and Pembrolizumab for Non–Small Cell Lung Cancer. Clinical Cancer Research 2016, 22: 3713-3717. PMID: 27252413, DOI: 10.1158/1078-0432.ccr-15-2998.Peer-Reviewed Original ResearchMeSH KeywordsAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsCarcinoma, Non-Small-Cell LungClinical Trials, Phase I as TopicHumansLung NeoplasmsNivolumabPrognosisProgrammed Cell Death 1 ReceptorRandomized Controlled Trials as TopicTreatment OutcomeConceptsCheckpoint inhibitorsClinical trialsAdvanced stage non-small lung cancerDeath-1 checkpoint inhibitorsLarge randomized clinical trialsNon-small lung cancerSecond-line docetaxelSurvivors 3 yearsBest supportive careSubset of patientsRandomized clinical trialsOverall survivalSupportive careCombination therapyLung cancerModest benefitPatientsPhase IImmunotherapyReliable predictorTherapyInhibitorsTrialsTreatmentNivolumab
2010
Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy
Haura EB, Camidge DR, Reckamp K, Chiappori A, Johnson F, Herbst R, Wong K, Carbone D. Molecular Origins of Lung Cancer: Prospects for Personalized Prevention and Therapy. Journal Of Thoracic Oncology 2010, 5: s207-s213. PMID: 20502275, DOI: 10.1097/jto.0b013e3181e2f682.Peer-Reviewed Original ResearchConceptsLung cancerPersonalized preventionLung cancer preventionCancer risk reductionCancer stem cellsCancer preventionClinical utilityMouse modelCancer advocatesTumor microenvironmentCancerEarly detectionMeeting presentationsPreventionRisk reductionTherapyStem cellsClinical workTreatmentChemopreventionImportant relevanceGenome-wide approaches
2009
VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab
Carbone DP, Salmon JS, Billheimer D, Chen H, Sandler A, Roder H, Roder J, Tsypin M, Herbst RS, Tsao AS, Tran HT, Dang TP. VeriStrat® classifier for survival and time to progression in non-small cell lung cancer (NSCLC) patients treated with erlotinib and bevacizumab. Lung Cancer 2009, 69: 337-340. PMID: 20036440, PMCID: PMC2891357, DOI: 10.1016/j.lungcan.2009.11.019.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCarcinoma, Non-Small-Cell LungDisease ProgressionDisease-Free SurvivalErlotinib HydrochlorideFemaleHumansLung NeoplasmsMaleMass SpectrometryMiddle AgedNeoplasm Recurrence, LocalPrecision MedicinePredictive Value of TestsProteomeQuinazolinesConceptsNon-small cell lung cancer patientsCell lung cancer patientsAdvanced NSCLC patientsCombination of erlotinibLung cancer patientsToxic regimenNSCLC patientsPretreatment serumCancer patientsWorse outcomesProteomic classifierBlinded mannerPatientsErlotinibBevacizumabVeriStratSurvivalTreatmentRegimenProgressionSerumTargeted drug delivery strategies to treat lung metastasis
Bar J, Herbst RS, Onn A. Targeted drug delivery strategies to treat lung metastasis. Expert Opinion On Drug Delivery 2009, 6: 1003-1016. PMID: 19663628, DOI: 10.1517/17425240903167926.Peer-Reviewed Original ResearchConceptsLung metastasesStandard clinical useMetastatic diseaseClinical trialsClinical useMost cancer patientsEarly clinical studiesCancer-specific antibodiesDrug delivery strategiesMain tumorTargeted drug delivery strategiesCancer patientsClinical studiesIntravascular devicesSolid tumorsMetastasisPreclinical developmentVascular fieldTreatmentTherapyTumorsAnticancer toolDiseaseDelivery strategiesTrialsSummary of Selected Presentations from the 8th Annual Targeted Therapy in Lung Cancer Symposium
Camidge R, Gaspar L, Goss G, Kelly K, Ramalingam S, Reckamp K, Simon G, Tsao M, West H, Herbst R, Johnson D, Bunn P, Govindan R. Summary of Selected Presentations from the 8th Annual Targeted Therapy in Lung Cancer Symposium. Journal Of Thoracic Oncology 2009, 4: 930-935. PMID: 19550249, DOI: 10.1097/jto.0b013e3181a9a03b.Peer-Reviewed Original ResearchConceptsLung cancerTargeted therapyGastrointestinal stromal tumorsCancer-related deathChronic myeloid leukemiaCancer SymposiumCytotoxic chemotherapyStromal tumorsMyeloid leukemiaBreast cancerCancerTherapyMolecular targetsCancer therapyTreatmentStriking improvementConsiderable optimismAnnual MeetingCancer genomicsChemotherapyInternational AssociationPatientsLeukemiaTumorsYears
2008
Multitargeted Inhibitors in Lung Cancer: New Clinical Data
Bar J, Herbst RS, Onn A. Multitargeted Inhibitors in Lung Cancer: New Clinical Data. Clinical Lung Cancer 2008, 9: s92-s99. PMID: 19419930, DOI: 10.3816/clc.2008.s.014.Peer-Reviewed Original ResearchConceptsLung cancerManagement of patientsCell lung cancerOngoing clinical trialsNew clinical dataCombination of therapiesTreatment arsenalMultitargeted therapyClinical trialsNovel therapiesClinical dataNovel agentsRadiation therapyTraditional chemotherapyTherapyCancerClinical useMalignant growthMultitargeted inhibitorsTreatmentPathwayMajor pathwayChemotherapyPatientsAgents
2007
Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference
Lynch TJ, Bonomi PD, Butts C, Davies AM, Engelman J, Govindan R, Herbst RS, Heymach JV, Johnson BE, Martins RG, Perez-Soler R, Riely GJ, Sandler AB, Sequist LV, Socinski MA, Wong KK, Hart CS. Novel Agents in the Treatment of Lung Cancer: Fourth Cambridge Conference. Clinical Cancer Research 2007, 13: 4583s-4588s. PMID: 17671145, DOI: 10.1158/1078-0432.ccr-07-0716.Peer-Reviewed Original ResearchPhase I participants’ views of quality of life and trial participation burdens
Cohen MZ, Slomka J, Pentz RD, Flamm AL, Gold D, Herbst RS, Abbruzzese JL. Phase I participants’ views of quality of life and trial participation burdens. Supportive Care In Cancer 2007, 15: 885-890. PMID: 17252219, DOI: 10.1007/s00520-007-0216-0.Peer-Reviewed Original ResearchConceptsTrial participationCurrent QoLPrevious cancer treatmentPhase I trialPhase I cancer trialsI cancer trialsSymptoms of diseaseStudy drugI trialCancer trialsPhysical complicationsTrial participantsSide effectsQoLCancer treatmentPhase ITrialsPotential participantsBurdenPerception of qualityProcedural burdenRespondent burdenParticipantsTreatmentBaseline ability
2000
9:00—9:15 Antiangiogenic Treatment with Endostatin Results in Uncoupling of Blood Flow and Glucose Metabolism in Human Tumors
Mullani N, Herbst R, Abbruzzese J, Charnsangavej C, Kim E, Tran H, Barron B, Lamki L, Gould K. 9:00—9:15 Antiangiogenic Treatment with Endostatin Results in Uncoupling of Blood Flow and Glucose Metabolism in Human Tumors. Molecular Imaging And Biology 2000, 3: 151. PMID: 11150754, DOI: 10.1016/s1095-0397(00)00063-7.Peer-Reviewed Original ResearchStandard uptake valueTumor blood flowBlood flowGlucose metabolismImaged tumorsTumor-bearing sitesStart of therapyTumor metabolic activityRegional blood flowNovel antiangiogenic agentsDays of treatmentNon-invasive imagingAntiangiogenic treatmentAntiangiogenic agentsPatientsDose levelsUptake valueTumorsHuman tumorsPercentage changePhase IOxygen-15Flourine-18TreatmentDose